Literature DB >> 21930481

TheTryton side branch stent.

Michael Magro1, Robert-Jan van Geuns.   

Abstract

The Tryton Side Branch Stent (Tryton Medical, Durham, NC, USA) is a dedicated bare metal stent developed to enhance the safety and efficacy of the two stent technique for the treatment of bifurcation lesions. The stenting technique, a "reverse culotte", secures the side branch (SB) with the placement of this dedicated stent in the proximal main vessel, across to the side branch while it facilitates the positioning of a conventional stent in the proximal to distal main vessel. The First-In-Man trial showed minimal SB late loss (0.17±0.35 mm) at six months while real world registry data reported target vessel revascularisation rates as low as 4% at the same time points and no stent thrombosis. The simplicity of the technique as well as the promising results have led to its widespread utilisation in Europe while in the US, a randomised trial is imminent and will serve for the device approval by the Food and Drug Administration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21930481     DOI: 10.4244/EIJV6SUPJA25

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  2 in total

1.  Side branch healing patterns of the Tryton dedicated bifurcation stent: a 1-year optical coherence tomography follow-up study.

Authors:  Maik J Grundeken; Hector M Garcia-Garcia; Robin P Kraak; P Woudstra; Daniel M de Bruin; Ton G van Leeuwen; Karel T Koch; Jan G Tijssen; Robbert J de Winter; Joanna J Wykrzykowska
Journal:  Int J Cardiovasc Imaging       Date:  2014-07-26       Impact factor: 2.357

2.  Comparative analysis of lumen enlargement mechanisms achieved with the bifurcation dedicated BiOSS) stent versus classical coronary stent implantations by means of provisional side branch stenting strategy: an intravascular ultrasound study.

Authors:  Robert J Gil; Jacek Bil; Aleksandra Michałek; Dobrin Vassiliev; Ricardo A Costa
Journal:  Int J Cardiovasc Imaging       Date:  2013-07-19       Impact factor: 2.357

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.